secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001104659-26-013412
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne appoints Steve Crouse as DSS President effective March 1; McManus transitions out
--------------------------------------------------------------------------------

- Dr. Matt McManus will transition from President, Diagnostics and Spatial Biology Segment effective March 1, 2026, and remain to support transition.
- Steve Crouse, previously SVP of Analytical Solutions, named successor; he joined in 2022 from Thermo Fisher Scientific.
- Crouse's employment agreement includes base salary of $505,000, target cash bonus of 75% of base, and equity awards valued at ~$170,000 one-time and ~$1.2M annual target.
- McManus's termination approved without cause; he will receive severance per employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000110465926013412/0001104659-26-013412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000110465926013412/tech-20260209x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-013412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer